Last reviewed · How we verify
dexmedetomidine hydrochloride for injection
At a glance
| Generic name | dexmedetomidine hydrochloride for injection |
|---|---|
| Also known as | Aibeining (trade name) |
| Sponsor | Peking University First Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- PENG Block With Dexmedetomidine in Older Adults (NA)
- Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery (PHASE4)
- Hypotensive Anesthesia for Orthognathic Surgery (PHASE4)
- Analgosedation With Ketamine, Nalbuphine, or Dexmedetomidine for Suture Removal in Children After Cleft Surgery (NA)
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
- Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children (PHASE4)
- Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: